The other opinion: nephrotoxicity of low-dose methotrexate - a problem which does not exist

被引：0
作者：
Fiehn, C. [1 ]
机构：
[1] ACURA Rheumazentrum Baden Baden, CH-76530 Baden, Switzerland
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2011年 / 70卷 / 10期
关键词：
Methotrexate; Nephrotoxicity; Renal function; Dose-dependency; Non-steroidal antirheumatic agents; RHEUMATOID-ARTHRITIS; DRUG; THERAPY;
D O I：
10.1007/s00393-011-0909-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The nephrotoxicity of methotrexate (MTX) is a phenomenon which is observed in high-dose therapy for treatment of malignant diseases. Even low-dose MTX therapy for treatment of rheumatic diseases is claimed to cause impairment in renal function. The necessity to adapt the dosage of MTX therapy for renal function disorders due to other causes however has first priority. The following article describes why nephrotoxicity of low-dose MTX has no clinical relevance and why in contrast non-steroidal anti-rheumatic drugs (NSARDs) are a problematic nephrotoxic group of substances and a long-term elimination from the therapeutic armamentarium for rheumatoid arthritis (RA) should be instigated.
引用
收藏
页码：825 / 826
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis: Therapeutic implications
    Bannwarth, B
    Pehourcq, F
    Lequen, L
    THERAPIE, 1997, 52 (02): : 129 - 132
  • [22] Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate
    Sibilia, J
    Liote, F
    Mariette, X
    REVUE DU RHUMATISME, 1998, 65 (04): : 267 - 273
  • [23] RENAL EFFECTS OF LOW-DOSE METHOTREXATE IN RHEUMATOID-ARTHRITIS
    SEIDEMAN, P
    MULLERSUUR, R
    EKMAN, E
    JOURNAL OF RHEUMATOLOGY, 1993, 20 (07) : 1126 - 1128
  • [24] Low-dose methotrexate: no adverse effect on bone mineral density
    Reactions Weekly, 2002, 916 (1) : 5 - 5
  • [25] THE USE OF LOW-DOSE METHOTREXATE IN REFRACTORY SARCOIDOSIS
    LOWER, EE
    BAUGHMAN, RP
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1990, 299 (03) : 153 - 157
  • [26] Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
    Ridker, Paul M.
    Everett, Brendan M.
    Pradhan, Aruna
    MacFadyen, Jean G.
    Solomon, Daniel H.
    Zaharris, Elaine
    Mam, Virak
    Hasan, Ahmed
    Rosenberg, Yves
    Iturriaga, Erin
    Gupta, Milan
    Tsigoulis, Michelle
    Verma, Subodh
    Clearfield, Michael
    Libby, Peter
    Goldhaber, Samuel Z.
    Seagle, Roger
    Ofori, Cyril
    Saklayen, Mohammad
    Butman, Samuel
    Singh, Narendra
    Le May, Michel
    Bertrand, Olivier
    Johnston, James
    Paynter, Nina P.
    Glynn, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) : 752 - 762
  • [27] Fatalities after low-dose therapy with methotrexate
    Buschmann C.
    Theile A.
    Tsokos M.
    Püschel K.
    Schulz F.
    Rechtsmedizin, 2007, 17 (2) : 89 - 94
  • [28] A case of emphysematous pyelonephritis in a patient with rheumatoid arthritis taking corticosteroid and low-dose methotrexate
    Watanabe, Hiroshi
    Suzuki, Ryoma
    Asano, Tomoyuki
    Shio, Kiori
    Iwadate, Haruyo
    Kobayashi, Hiroko
    Matsuoka, Toshimitsu
    Aikawa, Ken
    Ohira, Hiromasa
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2010, 13 (02) : 180 - 183
  • [29] Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? - A Case Report
    Jeiziner, Chiara
    Allemann, Samuel S.
    Hersberger, Kurt E.
    Schwabedissen, Henriette E. Meyer zu
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2022, 15 : 465 - 475
  • [30] Low-dose methotrexate in Rheumatology: A reinvented drug
    Gupta, Kushagra
    Ravindran, Vinod
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2025, 55 (01) : 59 - 68
12345